Rho GTPase activating protein 33 (ARHGAP33)

Rho GTPase activating protein 33 (ARHGAP33) is a member of the Rho GTPase-activating protein family, which plays key roles in downregulating Rho family GTPases by accelerating their intrinsic GTP hydrolysis, leading to inactivation of Rho protein signaling[1][2][4]. ARHGAP33 contains a PX (phox homology) domain, involved in phosphoinositide binding and cellular localization, and is predicted to function in the regulation of small GTPase-mediated signal transduction, postsynaptic assembly, and cytoskeletal remodeling[1][2]. It localizes to the cytoplasm, plasma membrane, and has activity at glutamatergic synapses, suggesting a significant role in neuronal function and organization[2]. The specificity of individual RHOGAPs, including ARHGAP33, for different Rho GTPase targets is still under investigation in the literature[4]. **Notes:** - There are no drugs or direct clinical biomarkers currently attributed specifically to ARHGAP33 in major sources, but other RHOGAPs are being investigated as disease targets[4]. - Synonyms such as "Sorting nexin 26" (SNX26) are sometimes used for this gene/protein[1]. - There is no evidence of misspelling or incorrect identification; ARHGAP33 is a recognized and characterized gene/protein[1][2][5]. - The role in disease is inferred primarily from general RHOGAP family functions and its involvement in cytoskeletal and synaptic regulation.

Other names

ARHGAP33SNX26Sorting nexin 26wu:fc76f02